Evidence map›Paper›PMID 27999163›Full record

ArticlemBio2016

Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells.

Robert C Kauffman, Taufiqur R Bhuiyan, Rie Nakajima, Leslie M Mayo-Smith, Rasheduzzaman Rashu, Mohammad Rubel Hoq, Fahima Chowdhury, Ashraful Islam Khan, Atiqur Rahman, Siddhartha K Bhaumik and 16 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 74 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Intracellular Expression of CTB inJournal of microbiology and biotechnology · 2023
    Article
  10. Article
  11. Frontiers in medicine · 2023
    Review
  12. Article
  13. A polyvalent multiepitope protein cross-protects againstProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  14. InactivatedJournal of microbiology and biotechnology · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Correlates of Protection for Cholera.The Journal of infectious diseases · 2021
    Article
  20. Systemic, Mucosal, and Memory Immune Responses following Cholera.Tropical medicine and infectious disease · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 2 countries.

Robert C KauffmanDivision of Infectious Disease, Department of Pediatrics, Emory University, School of Medicine, Atlanta, Georgia, USA.
Taufiqur R BhuiyanInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Rie NakajimaDepartment of Medicine, University of California, Irvine, California, USA.
Leslie M Mayo-SmithDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Rasheduzzaman RashuInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Mohammad Rubel HoqInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Fahima ChowdhuryInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Ashraful Islam KhanInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Atiqur RahmanInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Siddhartha K BhaumikDivision of Infectious Disease, Department of Pediatrics, Emory University, School of Medicine, Atlanta, Georgia, USA.
Levelle HarrisEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Justin T O'NealEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Jessica F TrostDivision of Infectious Disease, Department of Pediatrics, Emory University, School of Medicine, Atlanta, Georgia, USA.
Nur Haq AlamInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Algis JasinskasDepartment of Medicine, University of California, Irvine, California, USA.
Emmanuel DotseyDepartment of Medicine, University of California, Irvine, California, USA.
Meagan KellyDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Richelle C CharlesDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Peng XuNational Institute of Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic Chemistry, National Institutes of Health, Bethesda, Maryland, USA.
Pavol KováčNational Institute of Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic Chemistry, National Institutes of Health, Bethesda, Maryland, USA.
Stephen B CalderwoodDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Edward T RyanDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Phillip L FelgnerDepartment of Medicine, University of California, Irvine, California, USA.
Firdausi QadriInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Jens WrammertDivision of Infectious Disease, Department of Pediatrics, Emory University, School of Medicine, Atlanta, Georgia, USA jwramme@emory.edu jbharris@partners.org.
Jason B HarrisDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA jwramme@emory.edu jbharris@partners.org.
International Centre for Diarrhoeal Disease Research · BDMassachusetts General Hospital · USEmory University · USUniversity of California, Irvine · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
Reactions And Immunochemistry Of CarbohydratesZIADK059701 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KOVAC, PAVOL · 2009 to 2019
$9.5M
Protecutive immunity to human cholera in BangladeshU01AI058935 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CALDERWOOD, STEPHEN B., RYAN, EDWARD T. · 2003 to 2014
$7.8M
Training a New Generation of VaccinologistsT32AI074492 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Benjamin A Lopman · 2009 to 2026
$6.4M
Training program in vaccine development and public healthD43TW005572 · FIC · MASSACHUSETTS GENERAL HOSPITAL · PI QADRI, FIRDAUSI, RYAN, EDWARD T. · 2000 to 2025
$5.4M
O-Specific Polysaccharide Responses and CholeraR37AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Edward T. Ryan · 2020 to 2026
$5.1M
Innate and early B cell responses to V. choleraeR01AI103055 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HARRIS, JASON B · 2014 to 2018
$3.9M
O-Specific Polysaccharide Responses and CholeraR01AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2014 to 2018
$3.7M
Human B cell responses to a live attenuated cholera vaccineR01AI137127 · NIAID · EMORY UNIVERSITY · PI WRAMMERT, JENS PETER · 2018 to 2022
$1.9M
FIC NIH HHS D43 TW005572NIAID NIH HHS R01 AI103055NIAID NIH HHS R01 AI106878NIAID NIH HHS R01 AI137127NIAID NIH HHS R37 AI106878NIAID NIH HHS T32 AI074492NIAID NIH HHS U01 AI058935NIGMS NIH HHS T32 GM008169
6 · The paper itself

Abstract

We characterized the acute B cell response in adults with cholera by analyzing the repertoire, specificity, and functional characteristics of 138 monoclonal antibodies (MAbs) generated from single-cell-sorted plasmablasts. We found that the cholera-induced responses were characterized by high levels of somatic hypermutation and large clonal expansions. A majority of the expansions targeted cholera toxin (CT) or lipopolysaccharide (LPS). Using a novel proteomics approach, we were able to identify sialidase as another major antigen targeted by the antibody response to Vibrio cholerae infection. Antitoxin MAbs targeted both the A and B subunits, and most were also potent neutralizers of enterotoxigenic Escherichia coli heat-labile toxin. LPS-specific MAbs uniformly targeted the O-specific polysaccharide, with no detectable responses to either the core or the lipid moiety of LPS. Interestingly, the LPS-specific antibodies varied widely in serotype specificity and functional characteristics. One participant infected with the Ogawa serotype produced highly mutated LPS-specific antibodies that preferentially bound the previously circulating Inaba serotype. This demonstrates durable memory against a polysaccharide antigen presented at the mucosal surface and provides a mechanism for the long-term, partial heterotypic immunity seen following cholera. IMPORTANCE: Cholera is a diarrheal disease that results in significant mortality. While oral cholera vaccines are beneficial, they do not achieve equivalent protection compared to infection with Vibrio cholerae Although antibodies likely mediate protection, the mechanisms of immunity following cholera are poorly understood, and a detailed understanding of antibody responses to cholera is of significance for human health. In this study, we characterized the human response to cholera at the single-plasmablast, monoclonal antibody level. Although this approach has not been widely applied to the study of human bacterial infection, we were able to uncover the basis of cross-reactivity between different V. cholerae serotypes and the likely impact of prior enterotoxigenic Escherichia coli exposure on the response to cholera, as well as identify novel antigenic targets. In addition to improving our understanding of the repertoire and function of the antibody response to cholera in humans, this study has implications for future cholera vaccination efforts.

Indexed as

Immunologic MemorySingle-Cell AnalysisAdultAntibodies, BacterialAntibodies, MonoclonalAntibody FormationBacterial ToxinsB-LymphocytesCholeraCholera ToxinCross ReactionsEnterotoxinsEscherichia coli ProteinsHumansLipopolysaccharidesNeuraminidaseAntibodies, BacterialAntibodies, MonoclonalBacterial ToxinsCholera ToxinEnterotoxinsEscherichia coli Proteinsheat-labile enterotoxin, E coliLipopolysaccharidesNeuraminidaseO Antigens

Identifiers

PMID27999163
PMCPMC5181778
OpenAlexW2567516263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.